贝伐单抗
化疗
肿瘤科
医学
铂金
肺癌
PD-L1
内科学
免疫疗法
免疫检查点
免疫系统
一线治疗
癌症
免疫学
生物
生物化学
催化作用
作者
Émeline Orillard,Arjab Adhikari,Reem Malouf,François Calais,Corynne Marchal,Virginie Nerich
出处
期刊:The Cochrane library
[Elsevier]
日期:2024-08-13
卷期号:2024 (8)
标识
DOI:10.1002/14651858.cd015495
摘要
Lung cancer is a cancer of the elderly, with a median age at diagnosis of 71. More than one-third of people diagnosed with lung cancer are over 75 years old. Immune checkpoint inhibitors (ICIs) are special antibodies that target a pathway in the immune system called the programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway. These antibodies help the immune system fight cancer cells by blocking signals that cancer cells use to avoid being attacked by the immune system. ICIs have changed the treatment of people with lung cancer. In particular, for people with previously-untreated advanced non-small cell lung cancer (NSCLC), current first-line treatment now comprises ICIs plus platinum-based chemotherapy, rather than platinum-based chemotherapy alone, regardless of their PD-L1 expression status. However, as people age, their immune system changes, becoming less effective in its T cell responses. This raises questions about how well ICIs work in older adults.
科研通智能强力驱动
Strongly Powered by AbleSci AI